343 related articles for article (PubMed ID: 29714124)
1. Clinical application of pharmacogenetics in pain management.
Smith DM; Weitzel KW; Cavallari LH; Elsey AR; Schmidt SO
Per Med; 2018 Mar; 15(2):117-126. PubMed ID: 29714124
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
Smith DM; Weitzel KW; Elsey AR; Langaee T; Gong Y; Wake DT; Duong BQ; Hagen M; Harle CA; Mercado E; Nagoshi Y; Newsom K; Wright A; Rosenberg EI; Starostik P; Clare-Salzler MJ; Schmidt SO; Fillingim RB; Johnson JA; Cavallari LH
Genet Med; 2019 Aug; 21(8):1842-1850. PubMed ID: 30670877
[TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
[TBL] [Abstract][Full Text] [Related]
4. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
Ruano G; Kost JA
Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice.
Yamamoto PA; Conchon Costa AC; Lauretti GR; de Moraes NV
Pharmacogenomics; 2019 Aug; 20(13):971-982. PubMed ID: 31486733
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
[TBL] [Abstract][Full Text] [Related]
7. Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial.
Fulton CR; Zang Y; Desta Z; Rosenman MB; Holmes AM; Decker BS; Zhang Y; T Callaghan J; Pratt VM; Levy KD; Gufford BT; Dexter PR; Skaar TC; Eadon MT
Pharmacogenomics; 2019 Apr; 20(6):397-408. PubMed ID: 30784356
[No Abstract] [Full Text] [Related]
8. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GAPJM; Weide JV; Wilffert B; Swen JJ; Guchelaar HJ; Deneer VHM; van Schaik RHN
Eur J Hum Genet; 2022 Oct; 30(10):1105-1113. PubMed ID: 34267337
[TBL] [Abstract][Full Text] [Related]
9. Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.
Mosley SA; Hicks JK; Portman DG; Donovan KA; Gopalan P; Schmit J; Starr J; Silver N; Gong Y; Langaee T; Clare-Salzler M; Starostik P; Chang YD; Rajasekhara S; Smith JE; Soares HP; George TJ; McLeod HL; Cavallari LH
Contemp Clin Trials; 2018 May; 68():7-13. PubMed ID: 29535047
[TBL] [Abstract][Full Text] [Related]
10. Codeine and opioid metabolism: implications and alternatives for pediatric pain management.
Chidambaran V; Sadhasivam S; Mahmoud M
Curr Opin Anaesthesiol; 2017 Jun; 30(3):349-356. PubMed ID: 28323671
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids.
Knisely MR; Carpenter JS; Draucker CB; Skaar T; Broome ME; Holmes AM; Von Ah D
Appl Nurs Res; 2017 Dec; 38():107-110. PubMed ID: 29241501
[TBL] [Abstract][Full Text] [Related]
13. Reviewing pharmacogenetics to advance precision medicine for opioids.
Magarbeh L; Gorbovskaya I; Le Foll B; Jhirad R; Müller DJ
Biomed Pharmacother; 2021 Oct; 142():112060. PubMed ID: 34523422
[TBL] [Abstract][Full Text] [Related]
14. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
[TBL] [Abstract][Full Text] [Related]
15. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.
Thomas CD; Parvataneni HK; Gray CF; Deen JT; Prieto HA; Pulido LF; Elsey AR; Elwood EN; Starostik P; Gong Y; Fillingim RB; Johnson JA; Cavallari LH
Genet Med; 2021 Apr; 23(4):621-628. PubMed ID: 33420349
[TBL] [Abstract][Full Text] [Related]
16. Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center.
Ramsey LB; Prows CA; Chidambaran V; Sadhasivam S; Quinn CT; Teusink-Cross A; Tang Girdwood S; Dawson DB; Vinks AA; Glauser TA
Am J Health Syst Pharm; 2023 Jun; 80(13):852-859. PubMed ID: 36715063
[TBL] [Abstract][Full Text] [Related]
17. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.
Ballester P; Muriel J; Peiró AM
Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):261-275. PubMed ID: 35649041
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27335380
[TBL] [Abstract][Full Text] [Related]
20. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.
Jannetto PJ; Bratanow NC
Pharmacogenomics; 2009 Jul; 10(7):1157-67. PubMed ID: 19604091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
